Fig. 2
From: Serum IL-33, a new marker predicting response to rituximab in rheumatoid arthritis
Association between the four explanatory variables and EULAR response at 24 weeks after the first rituximab infusion in the combination of cohorts 1 and 2. Results from the multivariate analysis are presented as odds ratios (OR) (95% confidence intervals (CI)) for each factor. anti-CCP anti-cyclic citrullinated peptide antibody, DAS28-CRP Disease Activity Score in 28 joints by C-reactive peptide, IL interleukin, RF rheumatoid factor
